2-methyl-5-ethylindole | 85654-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-methyl-5-ethylindole
• 英文别名: 5-ethyl-2-methyl-1H-indole
• CAS: 85654-48-4
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: YQCBUXVHYQOBDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-methyl-5-ethylindole 在 K-16 作用下， 以 苯 为溶剂， 生成 2-methyl-5-vinylindole
  参考文献：
  名称：

  Zeiberlikh, F. N.; Starostenko, N. E.; Pavlova, L. V., Journal of Organic Chemistry USSR (English Translation), 1983, p. 388 - 392

  摘要：

  DOI：
• 作为产物：
  描述：

  acetone p-ethylphenylhydrazone 在 zinc(II) chloride 作用下， 以 甲苯 为溶剂， 反应 0.75h， 以36%的产率得到2-methyl-5-ethylindole
  参考文献：
  名称：

  Zeiberlikh, F. N.; Starostenko, N. E.; Pavlova, L. V., Journal of Organic Chemistry USSR (English Translation), 1983, p. 388 - 392

  摘要：

  DOI：

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES
  申请人：T3D Therapeutics, Inc.

  公开号：US20180153860A1

  公开（公告）日：2018-06-07

  The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.

  本发明提供了茚乙酸及其衍生物，以及用于治疗和/或预防认知障碍的方法。
• 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
  申请人：Allergan, Inc.

  公开号：US20130123215A1

  公开（公告）日：2013-05-16

  The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

  本发明涉及新颖的2,5-二氧代咪唑啉-1-基-3-苯基脲衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途，作为N-甲酰肽受体类似物-1（FPRL-1）受体的调节剂。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：HADIDA RUAH SARA S.

  公开号：US20090143381A1

  公开（公告）日：2009-06-04

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药用可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。